Published in:
01-02-2021 | Multiple Sclerosis | Brief Communication
Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod
Published in: Neurological Sciences | Issue 2/2021
Login to get accessAbstract/summary
Background
Fingolimod (FNG) is associated with the development of symptomatic macular edema (ME) in a small subset of multiple sclerosis (MS) patients. By using spectral domain optical coherence tomography (SD-OCT), an increase in the total macular volume (TMV) was rarely detected during the first months of treatment.
Objectives
The objective of this study is to assess whether FNG treatment leads to long-term macular changes in a real-life setting.
Methods
Sixty RRMS patients starting FNG, according to therapeutic indication, were enrolled at three Italian MS centers and followed for 2 years.
Results
The mean TMV did not change between baseline and the follow-up. No patients experienced visual acuity drop during the follow-up.
Conclusions
Initiation of FNG in MS is associated with a modest, not significant, increase in macular volume followed by no further significant changes over 2 years, highlighting the good safety profile of such treatment in MS.